Momenta Pharmaceuticals, Inc. (MNTA)

[flatlander_60048]

While elements of my conjecture may have occurred (the Bioequivalence test data being submitted and considered by FDA as an amendment to the ANDA), Dew has pointed out that Teva and NVS never reached an agreement on the notice to launch provision I spoke about. I had thought it was part of an out of court negotiated agreement. But apparently, it never went farther than discussions.

I do believe that Bill Marth got wind of the submital of the Bio Equivalence data and is spinning that it will considerably lengthen the ANDA review. Perhaps this revelation came out of the trial as others suspect. I'll go back to work now and quit conjuring things up.

FL